Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040679 | 0.78 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL3222311 | 0.76 | ACLY (0.40) | HTR2CHTR2ACYP2A6MEN1KMT2A | |
| SCHEMBL19506933 | 0.73 | PRMT5 (0.45) | KDM4EALDH1A1HPGDHSD17B10HTR2C | |
| SCHEMBL10284105 | 0.73 | HTR2C (0.41) | KDM4EALDH1A1HPGDHSD17B10HTR2C | |
| SCHEMBL18509284 | 0.73 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10HTR2C | |
| SCHEMBL3229178 | 0.72 | SLC6A2 (0.43) | KDM4EALDH1A1HPGDCYP1A2MAPT | |
| SCHEMBL24823830 | 0.72 | KDM4E (0.39) | KDM4EALDH1A1HPGDHSD17B10HTR2C | |
| SCHEMBL3220252 | 0.71 | ACLY (0.37) | KDM4EALDH1A1HPGDHSD17B10HTR2C | |
| SCHEMBL4054875 | 0.71 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL13640280 | 0.71 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | KDM4E 2494/4885ALDH1A1 298/4885HPGD 32/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | KDM4E 3087/4885ALDH1A1 1095/4885HPGD 141/4885 |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | KDM4E 3087/4885ALDH1A1 1095/4885HPGD 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.